Feature | October 15, 2014

Up to 15 patients will be enrolled in United Kingdom study


October 15, 2014 — Imricor Medical Systems, Inc. announced the first three cardiac ablation procedures were completed in the first clinical study that is evaluating the feasibility of their magnetic resonance (MR)-enabled products to treat atrial flutter. Prof. Reza Razavi, head of the Division of Imaging Sciences and Biomedical Engineering, King's College London, is the principal investigator for the study and performed the procedures along with Mark O'Neill, professor of cardiac electrophysiology and consultant cardiologist, Guy's and St. Thomas' NHS Trust in the United Kingdom, The prospective pilot study will enroll up to 15 patients at this center.

The Vision-MR Ablation Catheter and Advantage-MR EP Recorder/Stimulator System are currently being evaluated for the treatment of atrial flutter. The Vision-MR Ablation Catheter looks, feels and functions like a conventional ablation catheter. The Advantage-MR EP Recording/Stimulator System is also MR-enabled to avoid dangerous electromagnetic interactions with the MRI scanner and provide clear intra-cardiac electrograms and interference-free MR images. The system delivers the needed MR-enabled recording and pacing functions. Both products are used in conjunction with the iSuite image guidance platform that is provided by Philips.

"There have been many technical advances that have gone into this technology in order to create a system suitable for clinical use, and it has performed extremely well in the early phases of clinical trials. This is a groundbreaking study and we believe that there is a great future for MR-guided heart rhythm interventions. Not only is the requirement for X-rays removed, but for the first time the clinician is able to see the detailed anatomy of the heart, in real-time, during the procedure, and the therapeutic ablation lesions that have been created. The impact that such information could have on complex ablation procedures is enormous. We hope that this is a great step forward in the care and treatment of patients with abnormal heart rhythms," said Razavi.

For more information: www.imricor.com


Related Content

News | Pediatric Imaging

April 10, 2025 — Cincinnati Children’s and GE HealthCare will form a strategic research program focused on driving ...

Time April 10, 2025
arrow
News | Radiology Imaging

Jan. 15, 2025 — University of California, San Francisco (UCSF) Department of Radiology & Biomedical Imaging and GE ...

Time January 27, 2025
arrow
News | Contrast Media

Jan. 10, 2025 – Bayer has announced positive topline results of the Phase III QUANTI studies evaluating the efficacy and ...

Time January 14, 2025
arrow
News | Women's Health

Aug. 19, 2024 — GE HealthCare recently announced a collaboration with the University of California San Diego School of ...

Time August 29, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | RSNA

July 23, 2024 — Professional registration is open for RSNA 2024, the world’s largest radiology forum. This year’s theme ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 23, 2024 — Researchers at the National Institutes of Health (NIH) found that an artificial intelligence (AI) model ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 17, 2024 — Hyperfine, a groundbreaking medical device company that has redefined brain imaging with the world’s ...

Time July 17, 2024
arrow
News | Prostate Cancer

July 11, 2024 — GE HealthCare’s MIM Software, a global provider of medical imaging analysis and artificial intelligence ...

Time July 11, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
Subscribe Now